Haleon: Sensodyne maker strikes £500m deal to sell major division Business Haleon, the maker of Sensodyne toothpaste, has agreed a £500m deal to sell a major division outside of the US.
Haleon posts healthy first quarter update after UK job cuts Healthcare Revenue at Haleon was up in the first quarter despite its announcement yesterday that it would cut over 400 jobs in the UK, as the consumer healthcare firm posted a quarterly update in line with expectations.
Panadol painkiller-maker Haleon to buy shares from Pfizer as US pharma giant slims stake pharma fizer has committed to sell down its stake in a "slow and methodical" manner over time.
GSK spin-off Haleon offloads Chapstick brand for £400m to ‘simplify’ business January 25, 2024 Consumer healthcare company Haleon has agreed to sell its Chapstick lip balm brand to Yellow Wood Partners in a deal worth $510m (£401m) as part of efforts to "simplify" its business model.
Haleon: Chinese re-opening powers GSK spin-off to ‘consistent’ growth August 2, 2023 Strong sales of toothpaste and painkillers contributed to healthy results for Haleon, the newly-formed consumer healthcare firm spun out of GSK last year. In the first half of 2023, the Surrey-headquartered company’s revenue increased to £5.7bn, up 10.6 per cent compared to the same period last year. This was driven by Haleon’s ‘power brands’, such [...]
Haleon: Flu season and Chinese pain relief give GSK spin-out a boost May 3, 2023 A “strong” cold and flu season and the end of Chinese lockdowns contributed to a healthy revenue boost for Haleon, the spin-out of GSK’s consumer healthcare division. Organic revenues within the group were up 9.9 per cent, with operating profit hitting £627m – reflecting a large reduction in the costs of spinning out the business [...]
GSK brings in zosta lot more cash as drugs giant’s turnover boosted by shingles vaccine and HIV medicines April 26, 2023 Drugs giant GSK has posted better-than-forecast revenues for the first quarter thanks to strong sales of its shingles vaccine and HIV medicines. The FTSE 100 group saw earnings fall 15 per cent on a constant currency basis to £2.1bn in the first quarter as revenues dropped eight per cent to £7bn after sales of its Covid-19 treatment [...]